Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Ingraham, Charles H. IV ; Stalinska, Joanna ; Carson, Sean C. , et al. SCI REP-UK,2023,13(1):12236. DOI: 10.1038/s41598-023-39236-w PubMed ID: 37507404
More
Abstract: Glioblastomas are highly aggressive brain tumors for which therapeutic options are very limited. In a quest for new anti-glioblastoma drugs, we focused on specific structural modifications to the benzoyl-phenoxy-acetamide (BPA) structure present in a common lipid-lowering drug, fenofibrate, and in our first prototype glioblastoma drug, PP1. Here, we propose extensive computational analyses to improve the selection of the most effective glioblastoma drug candidates. Initially, over 100 structural BPA variations were analyzed and their physicochemical properties, such as water solubility (- logS), calculated partition coefficient (ClogP), probability for BBB crossing (BBB_SCORE), probability for CNS penetration (CNS-MPO) and calculated cardiotoxicity (hERG), were evaluated. This integrated approach allowed us to select pyridine variants of BPA that show improved BBB penetration, water solubility, and low cardiotoxicity. Herein the top 24 compounds were synthesized and analyzed in cell culture. Six of them demonstrated glioblastoma toxicity with IC50 ranging from 0.59 to 3.24 μM. Importantly, one of the compounds, HR68, accumulated in the brain tumor tissue at 3.7 ± 0.5 μM, which exceeds its glioblastoma IC50 (1.17 μM) by over threefold.
Purchased from AmBeed: 20173-04-0 ; 1539-42-0 ; 16867-03-1 ; 85622-93-1 ; 13207-66-4 ; 591-54-8 ; 6971-44-4 ; 18364-47-1 ; 45695-03-2 ; 2706-56-1 ; 21035-59-6 ; 90-45-9 ; 40154-75-4 ; 38767-72-5 ; 33630-99-8 ; 3731-52-0 ; 27854-90-6 ; 20173-24-4 ; 3731-53-1 ; 42017-89-0 ; 13010-47-4 ; 154-93-8 ; 3731-51-9 ; 56129-55-6 ; 671-16-9 ; 42017-89-0 ; 90-45-9 ...More
CAS No. : | 2706-56-1 | MDL No. : | MFCD00006367 |
Formula : | C7H10N2 | Boiling Point : | No data available |
Linear Structure Formula : | C5H4N(CH2)2NH2 | InChI Key : | XPQIPUZPSLAZDV-UHFFFAOYSA-N |
M.W : | 122.17 | Pubchem ID : | 75919 |
Synonyms : |
|
Chemical Name : | 2-Pyridylethylamine |
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | |
Hazard Statements: | H315-H319-H335 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With potassium carbonate; In dimethyl sulfoxide; at 115℃; for 1.5h;microwave irradiation; | Example 133Synthesis of 3-[(2-pyridin-2-yl)ethylamino)-5-[4-(quinolin-3-yl)-9H-carbazol-9-yl]pyridine-2-carboxamideStage 1:841 mg of <strong>[298709-29-2]2-cyano-3,5-difluoropyridine</strong>, 880 mg of 2-(2-aminoethyl)pyridine and 1.658 g of potassium carbonate in 12.5 ml of dimethyl sulphoxide are introduced into a 20 ml microwave tube reactor.The mixture is then heated in a microwave for 1 and a half hours at 115° C.The reaction medium is run into 100 ml of water and 100 ml of ethyl acetate.The aqueous phase is re-extracted twice with 50 ml of ethyl acetate.The combined organic phases are washed with water and then with a saturated aqueous solution of sodium chloride, dried over sodium sulphate and concentrated under reduced pressure.After purification by flash chromatography on 70 g of silica gel, elution being carried out with a mixture of ethyl acetate and cyclohexane (40/60 by volume), and the first eluted product being recovered, 549 mg of 2-cyano-5-fluoro-3-(2-pyridin-2-ylethylamino)pyridine are thus obtained in the form of a beige powder, the characteristics of which are the following:1H NMR spectrum (400 MHz, DMSO-d6, delta ppm): 3.02 (t, J=7.1 Hz, 2 H) 3.57 (q, J=6.8 Hz, 2 H) 6.94 (broad s, 1 H) 7.15-7.27 (m, 2 H) 7.33 (d, J=7.8 Hz, 1 H) 7.71 (td, J=7.6, 1.8 Hz, 1 H) 7.86 (d, J=2.4 Hz, 1 H) 8.51 (d, J=4.9 Hz, 1 H). | |
With potassium carbonate; In dimethyl sulfoxide; at 115℃; for 1.5h;Inert atmosphere; Microwave irradiation; | 841 mg of <strong>[298709-29-2]2-cyano-3,5-difluoropyridine</strong>, 880 mg of 2-(2-aminoethyl)pyridine and 1.658 g of potassium carbonate in 12.5 ml of dimethyl sulphoxide are charged to a 20 ml microwave tube-reactor.The mixture is then microwave-heated for 1.5 hours at 115° C.The reaction medium is run into 100 ml of water and 100 ml of ethyl acetate.The aqueous phase is re-extracted twice with 50 ml of ethyl acetate.The combined organic phases are washed with water and then with a saturated aqueous solution of sodium chloride, dried over sodium sulphate and concentrated under reduced pressure.After flash chromatography on silica gel (40-63 mum), elution being carried out with a mixture of ethyl acetate and cyclohexane (40:60 v/v), with the first eluted product being collected, 549 mg of 2-cyano-5-fluoro-3-(2-pyridin-2-ylethylamino)pyridine are obtained in the form of a beige powder, the characteristics of which are the following:1H NMR spectrum (400 MHz, delta in ppm, DMSO-d6): 3.02 (t, J=7.1 Hz, 2H); 3.57 (q, J=6.8 Hz, 2H); 6.94 (broad s, 1H); 7.15 to 7.27 (m, 2H); 7.33 (d, J=7.8 Hz, 1H); 7.71 (td, J=7.6 and 1.8 Hz, 1H); 7.86 (d, J=2.4 Hz, 1H); 8.51 (d, J=4.9 Hz, 1H) |
[ 6627-60-7 ]
(6-Methylpyridin-2-yl)methanamine
Similarity: 0.79